Director Geoffrey Pardo Buys $5 Million in SpyGlass Pharma Stock Post-IPO
SGP is trading near its 52-week low of $24.71 (5.9% above the low).
Summary
Director Geoffrey Pardo purchased $5 million worth of SpyGlass Pharma common stock on the open market, signaling strong insider confidence following the company's recent IPO.
Key Events · Ownership and Investor Activity · SGP
-
Significant Director Purchase
Director Geoffrey Pardo, through an affiliated entity, acquired 312,500 shares of common stock for $5,000,000.00 at a price of $16.00 per share on February 9, 2026.
-
Post-IPO Insider Confidence
This purchase was made at the IPO price and contributes to a cluster of insider buying activity following the company's successful initial public offering on February 9, 2026.
-
Preferred Stock Conversion
Pardo also reported the automatic conversion of 1,875,013 shares of Series D Preferred Stock into common stock, a routine event prior to the IPO closing.
Analysis · SGP · Industrial Applications And Services
Director Geoffrey Pardo, through an affiliated entity, made a substantial open market purchase of $5 million in SpyGlass Pharma common stock. This transaction, executed at the IPO price of $16.00 per share, signals strong insider confidence immediately following the company's initial public offering. This purchase contributes to a pattern of significant insider accumulation, with other directors also making notable buys post-IPO, collectively indicating a positive outlook from key stakeholders.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGP was trading at $26.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $835.4M. The 52-week trading range was $24.71 to $28.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.